Fidelio Healthcare Limburg concludes a non-exclusive cooperation agreement with Midas Pharma GmbH for the worldwide marketing of the service portfolio of Fidelio Healthcare.
Fidelio Healthcare Limburg was founded in early 2018 by an experienced management team from the CDMO industry with Heiner Hoppmann as the biggest shareholder. Soon after, the company took over the Mundipharma plant in Limburg as part of an asset deal.
The aim is to develop an independent medium-sized CDMO with a focus on business with medium-sized customers. The existing product portfolio includes solid, semi-solid and liquid dosage forms.
Fidelio sees great future opportunities in the field of soft gelatin capsule technology, which was newly established a year ago. Fidelio has a very experienced, well qualified development team and has already established itself as a competent partner for small innovative companies.
The company site is certified by the authorities from the EU, the USA, Latin America and Asia for the manufacture of pharmaceuticals. Since the takeover the Limburg site has already invested 7m € and around 30 new jobs have been created.
Providing products and services across the full industry value chain, Midas Pharma is a mid-sized pharmaceutical company that provides a wealth of expertise while connecting companies, people and knowledge. Our core competence is project management around pharmaceutical supply chains.
We provide API and FDF manufactured at our contract manufacturing partners. For each project or product we select the best match out of our manufacturing partner network. As a catalyst for collaboration, we have been helping our clients and partners unlock untapped potential for 30 years now.
Active in all major pharmaceutical markets, our affiliates serve as points of contact for our local customers as well as development and supply partners. They also provide local competence and networks.
As a virtual company, we create value by offering a wealth of expertise in project management while coordinating and connecting the complementary parts — people, knowledge and resources — to facilitate global pharmaceutical projects. For laboratory and production work, we cooperate with carefully selected specialist partners. This approach is the key to our flexibility in creating solutions through a wide array of services.
With more than 200 employees worldwide, we have expertise in all non-clinical stages of the pharmaceutical value chain — from precursor material of active ingredients to market-ready finished drug products. Two-thirds of our staff members have an academic degree, with one third holding PhDs.